<DOC>
	<DOCNO>NCT00419562</DOCNO>
	<brief_summary>Type 1 diabetes ( T1D ) autoimmune disease . This mean immune system ( part body help fight infection ) mistakenly attack destroys cell produce insulin ( islet cell find pancreas ) . As cell destroy , body 's ability produce insulin decrease . There evidence suggest repeat oral administration autoantigen ( protein immune system react ) may introduce protective immunity cause immune system stop attack . An early , large scale study do see oral insulin could delay prevent development Type 1 diabetes relative risk develop Type 1 diabetes . The overall result show entire study population , oral insulin delay prevent Type 1 diabetes . However , analysis do conclusion trial suggest potential beneficial effect subgroup participant . The participant seem benefit oral insulin high level insulin autoantibody direct insulin ( call mIAA ) . The Type 1 Diabetes TrialNet study group explore potential role oral insulin delay prevent Type 1 diabetes similar group people . The study also include secondary group individual different level risk primary cohort gather information future study .</brief_summary>
	<brief_title>Oral Insulin Prevention Diabetes Relatives Risk Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Eligible participant randomize receive either oral insulin ( 7.5 mg recombinant human insulin crystal ) placebo daily . All participant randomize study see study site follow-up evaluation , three six month randomization , every six month thereafter . Participants contact phone 6-monthly clinic visit assess change diabetes status , medication compliance adverse event . These phone contact occur approximately 3 month date participant previous clinic visit . At study visit , participant undergo assessment insulin production , immunologic status , overall health . As primary outcome measure , subject follow development type 1 diabetes conclusion study . The trial expect last approximately 7-8 year require amount information gather .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Have proband T1DM . A proband individual diagnose diabetes age 40 start insulin therapy within 1year diagnosis . Probands consider type 1 diabetes physician meet definition refer TrialNet Eligibility Committee . 2 . If proband parent , sibling child , study participant must 3 45 year age . If proband second third degree relative ( i.e . niece , nephew , aunt , uncle , grandparent , cousin , halfsibling ) , study participant must 320 year age . 3 . Willing sign Informed Consent Form . 4 . OGTT perform within 7 week prior randomization : fasting plasma glucose &lt; 110 mg/dL ( 6.1 mmol/l ) , 2 hour plasma glucose &lt; 140 mg/dL ( 7.8 mmol/l ) 5. mIAA confirm positive within previous six month . 6 . Two sample least one autoantibody mIAA positive within previous six month . 1 . Does satisfy inclusion criterion . Subjects mIAA positive autoantibody positive eligible randomization . 2 . Has severe active disease , e.g . chronic active hepatitis , severe cardiac , pulmonary , renal , hepatic , immune deficiency and/or disease likely limit life expectancy lead therapy immunosuppression time study . 3 . Prior participation trial prevention T1DM , e.g . nicotinamide , insulin , immunosuppressive drug . 4 . History treatment insulin oral hypoglycemic agent . 5 . History therapy immunosuppressive drug glucocorticoid within past two year period three month . 6 . Ongoing use medication know influence glucose , i.e . sulfonylurea , growth hormone , metformin , anticonvulsant , thiazide potassium deplete diuretic , beta adrenergic blocker , niacin . Subjects medication change suitable alternative , available , become eligible one month medication discontinue . 7 . Pregnant intend become pregnant study lactate . 8 . Deemed unlikely unable comply protocol . 9 . OGTT reveals Diabetes , Impaired Glucose Tolerance ( IGT ) , Impaired Fasting Glucose ( IFG ) . Diabetes define : fasting plasma glucose ³ 126 mg/dL ( 7 mmol/l ) , OR 2 hour plasma glucose ³ 200 mg/dL ( 11.1 mmol/l ) IGT define : fasting plasma glucose &lt; 126 mg/dL ( 7 mmol/l ) , 2 hour plasma glucose 140199 mg/dL ( 7.8 11mmol/l ) , IFG define : fasting plasma glucose 110125 mg/dL ( 6.16.9 mmol/l ) AND 2 hour plasma glucose &lt; 140 mg/dL ( 7.8 mmol/l ) 10 . Subject HLA DQA1*0102 , DQB1*0602 haplotype .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oral insulin</keyword>
	<keyword>autoantigen</keyword>
	<keyword>self tolerance</keyword>
	<keyword>oral tolerance</keyword>
	<keyword>DPT-1</keyword>
	<keyword>prevention</keyword>
	<keyword>`` risk '' develop type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>Type 1 diabetes TrialNet</keyword>
	<keyword>TrialNet</keyword>
</DOC>